Strategic Global Advisors LLC Takes Position in Insulet Corporation $PODD

Strategic Global Advisors LLC bought a new position in Insulet Corporation (NASDAQ:PODD) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 5,623 shares of the medical instruments supplier’s stock, valued at approximately $856,000.

Several other institutional investors also recently modified their holdings of the business. BlackRock Inc. purchased a new position in Insulet during the 2nd quarter valued at about $1,018,582,000. Norges Bank purchased a new stake in Insulet in the fourth quarter worth about $300,794,000. Arrowstreet Capital Limited Partnership increased its stake in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Man Group plc bought a new position in shares of Insulet during the second quarter valued at approximately $78,746,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Insulet during the second quarter valued at approximately $60,615,000.

Analysts Set New Price Targets

A number of analysts have recently commented on PODD shares. Raymond James Financial reissued an “outperform” rating and issued a $180.00 price target on shares of Insulet in a research report on Thursday, August 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $152.00 price objective (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Truist Financial reiterated a “hold” rating and set a $153.00 price objective (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Royal Bank Of Canada dropped their target price on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Bank of America dropped their target price on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $195.40.

Insulet Trading Up 0.2%

Shares of NASDAQ PODD opened at $143.38 on Thursday. The firm’s 50 day moving average price is $154.52 and its 200-day moving average price is $182.09. The company has a market cap of $9.94 billion, a PE ratio of 26.80, a P/E/G ratio of 1.13 and a beta of 1.10. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts expect that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insider Transactions at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.36% of the company’s stock.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, with adjusted EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million versus estimates of $787.4 million. Revenue increased 23.5% year over year, although investors remain focused on whether the company can sustain growth after its 2026 guidance reset. Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
• Neutral Sentiment: Insulet is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference, giving management an opportunity to address Omnipod demand, retention trends, manufacturing quality and its revised outlook. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Kestra Medical Technologies appointed Curtis Kopf, Insulet’s former global customer-experience executive, to a senior vice president role. The move is not an operating announcement from Insulet, but could draw attention to executive talent movement and customer-support capabilities in the diabetes-device market. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Multiple law firms are publicizing a federal securities class action against Insulet and certain officers, with an August 31 lead-plaintiff deadline. The complaints allege that the company made misleading statements or failed to disclose material information concerning manufacturing controls, product safety and compliance. The lawsuits are allegations, not established findings, but they increase legal, reputational and potential regulatory risks. Faruqi & Faruqi Insulet Securities Class Action Notice
• Negative Sentiment: Investor notices link the lawsuit to two voluntary Omnipod recalls or medical-device corrections affecting approximately 7 million Pods. Analysts reportedly questioned the scope of Insulet’s manufacturing and quality-control problems, cut valuation assumptions and reduced estimates despite management reiterating guidance. These issues threaten investor confidence in the company’s manufacturing story and could lead to additional scrutiny or costs. PODD Shareholder Alert from Levi & Korsinsky

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.